Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment

NCT00456014 · View on ClinicalTrials.gov ↗

Study Summary

This study will use pre-treatment positron emission topography and functional magnetic resonance imaging scans of the brain to predict the most effective antidepressant treatment for people with major depressive disorder.

Conditions Studied

Interventions

  • DRUG Escitalopram
  • DRUG Desipramine

Study Locations (1)

New York

  • Columbia University/New York State Psychiatric Institute — New York

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2006-09
Est. Completion 2012-05
Phase NA

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00456014

The ClinicalTrials.gov registry entry for NCT00456014 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 117 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 2 interventions — of which Escitalopram is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00456014 reports 1 study location spanning 1 distinct geographic area — top geographies include New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00456014 about?

NCT00456014 is a clinical study titled "Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment". This study will use pre-treatment positron emission topography and functional magnetic resonance imaging scans of the brain to predict the most effective antidepressant treatment for people with major depressive disorder.

What is the current status of trial NCT00456014?

This trial is currently completed. It is a NA study. The enrollment target is 37 participants. The study started on 2006-09. Estimated completion is 2012-05.

What conditions does trial NCT00456014 study?

This clinical trial studies the following conditions: Depression. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00456014?

The interventions under investigation include: Escitalopram (DRUG), Desipramine (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00456014?

This trial is sponsored by New York State Psychiatric Institute, which has 117 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00456014 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial